Editorial Comment
Residual Shunts After Transcatheter Closure of Patent Ductus Arteriosus A Major Concern or Benign "Techno-malady"? Larry A. Latson , MD M ulticenter trials of Rashkind's foam covered double umbrella device to nonsurgically V close the persistently patent ductus arteriosus (PDA) in the cardiac catheterization laboratory began in 1981. In the early years of these trials, success with this transcatheter technique was less than stellar when compared to the results of surgery. 12 Modification of the delivery technique, introduction of a larger device size, improvement in the release mechanism, and better definition of the appropriate patient population have lead to gradually improved results and greater confidence in the technique.3-5 However, reports of a relatively high inci-See p 2313 dence of residual leaks around or through the device appear, on the surface, to be legitimate reasons for concern about the ultimate role of the Rashkind device in the treatment of this common congenital defect.
In this issue of Circulation, Hosking et a16 review their data on 190 patients who underwent one or two attempts at transcatheter closure of PDA with the Rashkind PDA Occlusion Device® (also known as the Bard PDA umbrella). The data from Toronto continue to show that the implantation procedure is safe. There were no mortalities in this series (and there have been no procedure related mortalities reported in over 650 cases reported to the FDA in the current multicenter trials*). The device embolized in four patients (2%), but these were all in the authors' early experience and occurred at a time when the release mechanism of the device was undergoing modification. The only complications noted by the authors after successful implantation of a device were transient hemolysis in two patients (1%) *Personal communication with clinical affairs manager of USCI and early bacteremia in one who did not receive prophylactic antibiotics for the procedure. These results are similar to those recently reported from other centers participating in the FDA-monitored multicenter trials. [3] [4] [5] Although safety does not appear to be a problem, the issue of residual shunts after use of the Rashkind device is more complex. Hosking et al have nicely detailed the prevalence of residual shunting when patients have been followed for up to 40 months. They found that 53% of their patients had residual shunts detectable by Doppler echocardiography 24 hours after device placement. Spontaneous closures decreased this prevalence to 34% at 1 year, 19% at 2 years, and 11% at 40 months. A repeat occlusion procedure was successful in nine additional patients who had a residual shunt large enough to be associated with a continuous murmur after their first procedure, and therefore the final prevalence of Doppler-detectable leaks 40 months after first device placement with the authors' protocol for nonsurgical treatment of PDA was 8%. The findings of late spontaneous closures and successful repeat occlusions are encouraging in some respects, but the prospect of leaving 8% of patients with a residual leak after 31/2 years is, at first glance, somewhat disconcerting.
The problem with comparing modern data on the PDA occlusion device with historical data on PDA surgery is that we tend to neglect the influence that the development of more sensitive diagnostic methods could have on our perception of the success of the procedures. Since the early 1980s, Doppler echocardiography has been available to detect left to right shunting through a PDA. In the presurgical and preantibiotic era, patients were detected only if they had a distinctly abnormal physical examination. This clinically diagnosable group of patients clearly had a poor prognosis with only about half surviving past the age of 30 and few surviving into their 60s.7,8 The success of surgery was readily apparent clinically and the gold standard of success was elimination of the characteristic continuous murmur. Residual nonspecific systolic murmurs were consistently reported in about 20% of postoperative patients,9,10 but unless their murmur was unusually loud or widespread these patients were assumed to be essentially normal," and there has been no new epidemiological evidence in the last 20 years to indicate that they should be treated otherwise.
Doppler ultrasound technology came into widespread use just as the Rashkind PDA Occlusion Device trials were beginning. Because of this, nearly every patient who has had one of these devices implanted has had multiple Doppler echocardiographic examinations to look for residual leaks, and these exams instead of clinical exams have become the yardstick for success of the technique. On the other hand, because surgical "closure" of the PDA has such a long history of unquestioned excellent results most physicians have not seen a need to obtain routine echocardiograms on clinically normal postoperative patients. Recently, however, the echocardiogram has been aimed at a few series of postoperative patients after PDA ligation, and the results have been surprising. As Hosking points out, two separate recent studies12,13 have shown residual Doppler detectable shunts in 6% and 23% of postoperative patients who had no clinical evidence of a residual PDA. Historically, such clinically normal postoperative patients have done extremely well when treated as though they had completely normal hearts. Our dilemma then is whether to accept that historical data at face value and not worry about trivial leaks detectable only by Doppler echocardiography or to follow the common sentiment that any patient known to have any PDA should have it closed.
The only real concern for patients with a trivial PDA is the possibility of developing endarteritis in or around the ductus. Historically, this was a major concern. Before the widespread availability of antibiotics (and surgery), endocarditis was the cause of death in nearly half of all (clinically diagnosed) patients dying from PDA.7-9 Because of this sobering fact, as surgery became safer, the indication for operation generally became the mere presence of a PDA, even if it was small and asymptomatic. We must remember, however, that these recommendations evolved at a time when Doppler echocardiography was not available, and recent studies indicate that trivial PDAs not detectable by clinical exam may be much more common in the general population than previously suspected. Houston et al14 estimated that such "silent" PDAs may be detectable by Doppler echocardiography in as many as 0.5% of asymptomatic children presenting with innocent murmurs. In spite of this, neither Houston et al nor I were able to locate a documented case of endocarditis in a patient whose sole underlying cardiovascular abnormality was a trivial and clinically silent ductus. In the multicenter trial of the Rashkind PDA Occluder there has been one late case of endarteritis (of which Hosking et al were not aware) reported in a patient with a clearly audible residual continuous murmur. This patient reportedly was not following the recommended endocarditis prophylaxis precautions while awaiting placement of a second device.* There have been no late cases of infection in over 1,800 patientyears of follow-up in postimplantation patients who had no clinical evidence of a residual shunt (whether they had a Doppler detectable leak or not).
If we examine the Hosking data on the Rashkind PDA Occlusion Device in terms of the clinical results instead of the Doppler results, then the transcatheter technique appears much more attractive. At the end of the study, the authors were following 34 patients with Doppler detectable leaks around their devices (at least 6 months after device implantation). Ninetyfour percent of these patients had either no murmur (76%) or a soft systolic murmur (18%). Only two patients, 1% of those originally enrolled in the study, had a residual continuous murmur. There is little doubt that these two patients with a clinically detectable residual shunt need to have their residual PDAs closed, and the authors have shown that this can be done with a second device.
The Rashkind PDA Occlusion Device is not applicable to all patients with a PDA. Hosking et al limited its use to patients weighing over 6 kg and having a ductus diameter less than 8 mm. In our experience, about 80% of unselected patients (excluding premature infants) with an isolated PDA are candidates for the device using similar criteria.5 If transcatheter closure is presented as an alternative to surgery, we have found that patients (and/or their parents) overwhelmingly prefer the transcatheter procedure, even if they must sign all the consent forms explaining the experimental nature of the procedure. To the average patient, the prospect of outpatient closure of the ductus through a small skin nick in the groin and minimal recovery time outweighs the uncertainty of the long-term results when compared to the prospect of thoracic surgery with its attendant perioperative incisional pain, requirement for hospitalization, and lifelong scar.
In an earlier era, before the advent of Doppler echocardiography, transcatheter closure of PDA using the Rashkind device probably would have been quickly judged to be at least as effective as surgical ligation. Over 50 years of experience with postsurgical patients tells us that physical examination is probably good enough to detect residual shunting significant enough to leave a patient at risk for later endarteritis. We should not ignore the Doppler echocardiographic data that tells us that tiny, silent leaks are more common than expected after clinically successful closures with the transcatheter device. We also, however, should not ignore the increasing evidence that such silent shunts are more common than we previously suspected in both postsurgical patients and in the general population, without apparent adverse effects. If we judge surgery and transcatheter procedures in the same light, I think that there is *Personal communication with clinical affairs manager of USCI Division, C.R. Bard, Inc. (sponsor of the multicenter trials of the Rashkind PDA Occlusion Device®). sufficient evidence of both safety and efficacy to recommend the transcatheter technique as an alternative to surgery and, in the minds of most patients, I think it will be the procedure of choice when it becomes more widely available.
